Connection

CHRISTIE BALLANTYNE to Pharmacogenetics

This is a "connection" page, showing publications CHRISTIE BALLANTYNE has written about Pharmacogenetics.
Connection Strength

0.297
  1. Empowering personalized pharmacogenomics with generative AI solutions. J Am Med Inform Assoc. 2024 May 20; 31(6):1356-1366.
    View in: PubMed
    Score: 0.195
  2. Genetic testing in ambulatory cardiology clinics reveals high rate of findings with clinical management implications. Genet Med. 2021 12; 23(12):2404-2414.
    View in: PubMed
    Score: 0.040
  3. Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. Nat Commun. 2014 Oct 28; 5:5068.
    View in: PubMed
    Score: 0.025
  4. Rare LPL gene variants attenuate triglyceride reduction and HDL cholesterol increase in response to fenofibric acid therapy in individuals with mixed dyslipidemia. Atherosclerosis. 2014 Jun; 234(2):249-53.
    View in: PubMed
    Score: 0.024
  5. A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis. J Am Coll Cardiol. 2005 May 17; 45(10):1611-9.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.